Tower Research Capital LLC TRC Sells 3,475 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)

Tower Research Capital LLC TRC decreased its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 60.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,248 shares of the company’s stock after selling 3,475 shares during the quarter. Tower Research Capital LLC TRC’s holdings in HUTCHMED were worth $41,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of HCM. China Universal Asset Management Co. Ltd. lifted its position in shares of HUTCHMED by 353.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company’s stock valued at $65,000 after buying an additional 2,801 shares during the last quarter. Baillie Gifford & Co. lifted its position in shares of HUTCHMED by 7.2% during the 4th quarter. Baillie Gifford & Co. now owns 144,969 shares of the company’s stock valued at $2,625,000 after buying an additional 9,694 shares during the last quarter. Vanguard Personalized Indexing Management LLC purchased a new position in shares of HUTCHMED during the 3rd quarter valued at $196,000. Hsbc Holdings PLC purchased a new position in shares of HUTCHMED during the 3rd quarter valued at $380,000. Finally, Hennion & Walsh Asset Management Inc. lifted its position in shares of HUTCHMED by 89.5% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 51,735 shares of the company’s stock valued at $876,000 after buying an additional 24,437 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HCM. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of HUTCHMED in a research report on Friday, January 12th. StockNews.com raised HUTCHMED from a “hold” rating to a “buy” rating in a research report on Wednesday, March 27th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.70.

HUTCHMED Stock Up 4.3 %

HCM traded up $0.80 during trading on Thursday, reaching $19.56. 120,033 shares of the company were exchanged, compared to its average volume of 122,944. The company’s 50-day moving average is $16.75 and its two-hundred day moving average is $16.82. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.60 and a current ratio of 2.72. HUTCHMED has a 12-month low of $10.68 and a 12-month high of $20.73.

HUTCHMED Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.